新闻
ASND
--
0.00%
--
以下是对冲基金对 Ascendis Pharma A/S (ASND) 的看法
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don’t make them change their opinion towards a company. This time it may be different. The coronavirus...
Insider Monkey · 10小时前
Ascendis Pharma 报告美国商业推出 SKYTROFA 用于治疗小儿生长激素缺乏症
Ascendis Pharma A/S (NASDAQ:ASND), today announced the U.S. commercial launch of SKYTROFA (lonapegsomatropin-tcgd), its once-weekly treatment for the treatment of pediatric patients one year and older who weigh at least
Benzinga · 3天前
Ascendis Pharma A/S 宣布 SKYTROFA®(Lonapegsomatropin-tcgd)在美国商业上市,这是 FDA 批准的第一个也是唯一一个每周一次的儿童生长激素缺乏症治疗方法
COPENHAGEN, Denmark, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), today announced the U.S. commercial launch of SKYTROFA (lonapegsomatropin-tcgd), its once-weekly treatment for the treatment of pediatric patients one year and older...
GlobeNewswire · 3天前
Ascendis Pharma A/S 在美国骨与矿物质研究学会 2021 年年会上宣布 TransCon PTH 和 TransCon CNP 的报告
Ascendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company using its innovative TransCon technologies to potentially create new treatments to make a meaningful difference in patients' lives, today announced
Benzinga · 09/30 20:03
Ascendis Pharma A/S 在美国骨与矿物研究学会 2021 年年会上宣布 TransCon™ PTH 和 TransCon™ CNP 的报告
– Late-breaking oral presentation will feature a comprehensive review of 58-week results from the company’s Phase 2 PaTH Forward Trial – COPENHAGEN, Denmark, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company...
GlobeNewswire · 09/30 20:01
Ascendis Pharma A/S 宣布股份回购计划
COPENHAGEN, Denmark, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new treatments that make a meaningful difference in patients’ ...
GlobeNewswire · 09/29 20:01
辉瑞的生长激素候选药物 FDA 审查推迟了 3 个月
Pfizer Inc's (NYSE: PFE) effort to defend its growth hormone franchise against a new, more convenient competitor has hit a snag. 
Benzinga · 09/27 13:23
医学的黄金时代即将来临。发挥最新创新的 10 只股票。
Our 2021 healthcare roundtable highlights the technologies and treatments changing the face of medicine, and the companies that could benefit.
Barrons.com · 09/27 11:53
医学的黄金时代即将来临。 10 种投资方式。
Our 2021 healthcare roundtable highlights the technologies and treatments changing the face of medicine, and the companies that could benefit.
Barrons.com · 09/25 00:29
Ascendis Pharma 强调了来自第 2 阶段 Path 前向试验的平均骨矿物质密度数据,显示持续正常化,26-58 周之间 BMD Z 分数稳定
– Data from subjects with available dual energy x-ray absorptiometry (DXA) scans demonstrated stabilization of BMD, in alignment with observed bone turnover markers previously reported – COPENHAGEN, Denmark,
Benzinga · 09/22 20:29
Ascendis Pharma A/S 公布了来自第 2 阶段 Path 前向试验的平均骨矿物质密度 (BMD) 数据,证明 BMD Z 分数在 26 至 58 周之间持续正常化和稳定
– Data from subjects with available dual energy x-ray absorptiometry (DXA) scans demonstrated stabilization of BMD, in alignment with observed bone turnover markers previously reported – COPENHAGEN, Denmark, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Ascendis Phar...
GlobeNewswire · 09/22 20:27
Ascendis (ASND) 寻求 FDA 批准新免疫疗法研究
Ascendis (ASND) plans to develop a sustained-release immunotherapy to treat advanced cancer developed using its TransCon platform.
Zacks · 09/08 14:57
Ascendis Pharma A/S 宣布即将举行的投资者报告会
COPENHAGEN, Denmark, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new treatments that make a meaningful difference in patients’ ...
GlobeNewswire · 09/07 21:09
Ascendis Pharma A/S 提交研究性新药申请以启动 TransCon™ IL-2 β/γ 临床项目
– TransCon IL-2 β/γ is an investigational long-acting prodrug designed to improve cancer immunotherapy through the sustained systemic release of an IL-2 variant with potential for prolonged activation of IL-2Rβ/γ with low Cmax – COPENHAGEN, Denmark, Sept. ...
GlobeNewswire · 09/07 20:59
Ascendis Pharma 寻求 FDA 批准以启动晚期癌症患者的 TransCon 试验
MT Newswires · 09/07 17:45
Ascendis Pharma 的定价为每个 ADS 160 美元
MT Newswires · 09/02 04:11
ADR 收高,Ascendis Pharma 交易活跃
marketwatch.com · 09/01 20:46
The Daily Biotech Pulse:默克发布双倍积极消息,安斯泰来自愿暂停基因治疗研究,Ascendis 产品
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31)
Benzinga · 09/01 11:32
Ascendis Pharma A/S 宣布拟公开发售 ADS
Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technologies to potentially create new treatments that make a meaningful difference in patients' lives, today announced that it has commenced an under...
GlobeNewswire · 08/31 20:01
生物技术投资者注意:在日历上标记 9 月 PDUFA 日期
August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining.
Benzinga · 08/31 18:00
微牛提供丰富的实时ASND股票新闻,让你可以通过多个平台了解ASND股票行情最新动态,这些免费的Ascendis制药新闻可以帮助你做出明智投资。
ASND 简况
Ascendis Pharma A/S是一家丹麦的生物制药公司,主要生产罕见病治疗产品。该公司利用其TransCon技术进行治疗。该技术可应用于蛋白质、肽和小分子在内的现有药物疗法,以生产前药。该公司总部位于丹麦哥本哈根,在德国海德堡和加利福尼亚州的帕洛阿尔托设有办事处。